Free stock market and financial news API
Instant access to global stock market and finance news also including funds, crypto and more along with comprehensive sentiment analysis.
{
"meta": {
"found": 287,
"returned": 5,
"limit": 5,
"page": 1
},
"data": [
{
"uuid": "682cdb4b-31af-47d9-98d5-6919ed501f08",
"title": "Fauci said FDA panel's recommendation shows J&J vaccine 'should have been a two-dose vaccine to begin with'",
"description": "Fauci called an FDA panel's recommendation to authorize J&J boosters",
"keywords": "",
"snippet": "Dr. Anthony Fauci said the Johnson & Johnson COVID-19 vaccine likely \"should have been a two-dose vaccine to begin with.\"\n\nAn FDA panel of outside experts last ...",
"url": "https://www.businessinsider.com/fauci-jj-vaccine-should-have-been-a-two-dose-vaccine-2021-10",
"image_url": "https://i.insider.com/616c6dd638c196001830472c?width=1200&format=jpeg",
"language": "en",
"published_at": "2021-10-17T19:05:13.000000Z",
"source": "businessinsider.com",
"relevance_score": null,
"entities": [
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.294872,
"sentiment_score": 0.10115,
"highlights": [
{
"highlight": "Anthony Fauci said the Johnson & Johnson COVID-19 vaccine likely \"should have been a two-dose vaccine to begin with.\"\n\nAn FDA panel of outside experts last week recommended that the agency authorize J&J's request to offer a booster dose.",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Anthony Fauci, the longtime director of the National Institute of Allergy and Infectious Diseases, said Sunday that a recent recommendation by a US Food and Drug Administration advisory panel indicated that the Johnson & Johnson COVID-19 vaccine should've required two doses from the get-go.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "a62d1fed-3f72-4318-96e5-c02e519b6adb",
"title": "Fictional detective Olympics: The oldest, the best, the most murdery",
"description": "Ranking the Sherlocks of the world, in multiple categories, produces winners you might not expect. Sorry, Batman.",
"keywords": "",
"snippet": "Grab your magnifying glass and get ready to investigate as Mashable uncovers Big/Little Mysteries.\n\nWho doesn't like a good fictional detective? The genre, whic...",
"url": "https://mashable.com/article/best-fictional-detectives?taid=616c4cbfafae3500014412bd",
"image_url": "https://helios-i.mashable.com/imagery/articles/07h5YOx2XiMP3Ep6lMEdl9t/hero-image.fill.size_1200x675.v1634475910.jpg",
"language": "en",
"published_at": "2021-10-17T19:05:08.000000Z",
"source": "niemanlab.org",
"relevance_score": null,
"entities": [
{
"symbol": "SONY",
"name": "Sony Group Corporation",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 4.805746,
"sentiment_score": 0.6676,
"highlights": [
{
"highlight": "Credit: sony pictures\n\nGold medal: Los Angeles. Silver: New York City. Tied for bronze: London, San Francisco and Miami.\n\nIt wouldn't be an Olympics without the opportunity for team sports. When applied to detective fiction, this raises the question: Which city has the largest number of famous fictional detectives?",
"sentiment": 0.6676,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "9cad7f74-7b32-4ef6-ac5f-35ef222f043b",
"title": "Looking for Business Partners",
"description": "Hi,\n\nI see an business opportunity and am looking for serious people interested in crypto, NFT and programming to discuss further. Please PM Me. No trolls...",
"keywords": "",
"snippet": "Special Events Tech Show Central\n\nInfoTech Clinics Hardware Clinic Hardware Clinic Knowledge Base Personal Projects and Reviews Den Notebook Clinic The Tablet D...",
"url": "https://forums.hardwarezone.com.sg/threads/looking-for-business-partners.6623879/",
"image_url": "https://forums-media.hardwarezone.com.sg/data/assets/logo/hwz-logo-1500.png",
"language": "en",
"published_at": "2021-10-17T18:55:57.000000Z",
"source": "forums.hardwarezone.com.sg",
"relevance_score": null,
"entities": [
{
"symbol": "SONY",
"name": "Sony Group Corporation",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 12.922195,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Console Gaming Handheld and Mobile Gaming Gaming Bazaar The House of Displays The House of Display Knowledge Base Home Theatre & Audiophiles Headphones, Earphones and Portable Media Devices The Tablet Den The iPad Sanctum Digital Cameras & Photography Mobile Communication Technology Android User Group Huawei User Group OPPO User Group SAMSUNG User Group SONY",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "72c82c13-bf2a-4765-8b73-65dcfc7a0f6d",
"title": "U.S. Coast Guard boards ship in connection with California oil spill By Reuters",
"description": "U.S. Coast Guard boards ship in connection with California oil spill",
"keywords": "",
"snippet": "© Reuters. FILE PHOTO: Workers rake up globs of crude oil after more than 3,000 barrels (126,000 gallons) of crude oil leaked from a ruptured pipeline into the...",
"url": "https://www.investing.com/news/commodities-news/us-coast-guard-boards-ship-in-connection-with-california-oil-spill-2646089",
"image_url": "https://i-invdn-com.investing.com/news/LYNXNPEB7405M_L.jpg",
"language": "en",
"published_at": "2021-10-17T18:45:43.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "AMPY",
"name": "Amplify Energy Corp.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Energy",
"match_score": 20.946287,
"sentiment_score": 0.3612,
"highlights": [
{
"highlight": "Amplify Energy (NYSE: ), which owns the pipeline, has said it was \"pulled like a bowstring\" about 105 feet (32 meters) from where it should have been.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "df172485-ce0f-4638-a354-926f4b3f164e",
"title": "U.S. Coast Guard Boards Vessel That Dragged Anchor Near Pipeline",
"description": "(Bloomberg) — The U.S. Coast Guard boarded a container ship that dragged its anchor in close proximity to a Southern California undersea pipeline that was the…",
"keywords": "",
"snippet": "Article content\n\n(Bloomberg) — The U.S. Coast Guard boarded a container ship that dragged its anchor in close proximity to a Southern California undersea pipe...",
"url": "https://financialpost.com/pmn/business-pmn/u-s-coast-guard-boards-vessel-that-dragged-anchor-near-pipeline",
"image_url": "https://storage.googleapis.com/pmd-stage-northamerica-northeast1-dcs-static-files/8.1.3/websites/images/fp/favicon-fp.ico",
"language": "en",
"published_at": "2021-10-17T12:38:37.000000Z",
"source": "financialpost.com",
"relevance_score": null,
"entities": [
{
"symbol": "AMPY",
"name": "Amplify Energy Corp.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Energy",
"match_score": 36.548035,
"sentiment_score": 0.6597,
"highlights": [
{
"highlight": "The growth of marine life around the breach in the Amplify Energy Corp. pipeline indicated that an anchor dragged by the line a while ago, rather than recently, U.S. Coast Guard officials said last week, adding that they were looking at Jan. 24 and Jan. 25 as dates of interest because of a large storm at that time.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "94ce682d-40c6-46cd-8e15-65d39ea1088c",
"title": "Can Pfizer and GlaxoSmithKline Beat Johnson & Johnson's RSV Vaccine?",
"description": "J&J has set a high bar for its rivals.",
"keywords": "",
"snippet": "There's a big battle shaping up with several large drugmakers developing respiratory syncytial virus (RSV) vaccines. Johnson & Johnson (NYSE:JNJ) recently annou...",
"url": "https://www.fool.com/investing/2021/10/17/can-pfizer-and-glaxosmithkline-beat-johnson-johnso/",
"image_url": "https://optimize.foolcdn.com/?url=https%3A%2F%2Fg.foolcdn.com%2Fmisc-assets/jester.png&w=400&op=resize",
"language": "en",
"published_at": "2021-10-17T18:31:00.000000Z",
"source": "fool.com",
"relevance_score": null,
"entities": [
{
"symbol": "GSK",
"name": "GlaxoSmithKline plc",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 27.570467,
"sentiment_score": 0.09735,
"highlights": [
{
"highlight": "In this Motley Fool Live video recorded on Oct. 6, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J set a high bar for Pfizer (NYSE:PFE) and GlaxoSmithKline (NYSE:GSK) to top.\n\nKeith Speights: Let's switch to a non-COVID development now.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Do you think these results set a tough bar for Pfizer and GlaxoSmithKline, both of which are also developing RSV vaccines?\n\nBrian Orelli: This is a phase 2 study that had 5,800 adults over the age of 65. As you mentioned, it's a fairly large phase 2 study. There are phase 3 studies even larger, it's 23,000 people.",
"sentiment": -0.128,
"highlighted_in": "main_text"
},
{
"highlight": "Creating a vaccine that's 80 percent effective from having to require medical intervention I think definitely sets a high bar for Pfizer and GlaxoSmithKline. Then there's actually quite a few companies behind them, including Moderna, which will also have to meet that bar, assuming it holds up between the phase 2 study and the phase 3 study.",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "Can Pfizer and GlaxoSmithKline Beat Johnson & Johnson's RSV Vaccine?",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "PFE",
"name": "Pfizer Inc.",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 19.094059,
"sentiment_score": 0.09735,
"highlights": [
{
"highlight": "In this Motley Fool Live video recorded on Oct. 6, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J set a high bar for Pfizer (NYSE:PFE) and GlaxoSmithKline (NYSE:GSK) to top.\n\nKeith Speights: Let's switch to a non-COVID development now.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Do you think these results set a tough bar for Pfizer and GlaxoSmithKline, both of which are also developing RSV vaccines?\n\nBrian Orelli: This is a phase 2 study that had 5,800 adults over the age of 65. As you mentioned, it's a fairly large phase 2 study. There are phase 3 studies even larger, it's 23,000 people.",
"sentiment": -0.128,
"highlighted_in": "main_text"
},
{
"highlight": "Creating a vaccine that's 80 percent effective from having to require medical intervention I think definitely sets a high bar for Pfizer and GlaxoSmithKline. Then there's actually quite a few companies behind them, including Moderna, which will also have to meet that bar, assuming it holds up between the phase 2 study and the phase 3 study.",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "Can Pfizer and GlaxoSmithKline Beat Johnson & Johnson's RSV Vaccine?",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": "NYSE",
"exchange_long": "New York Stock Exchange",
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 38.46233,
"sentiment_score": 0.41895,
"highlights": [
{
"highlight": "Johnson & Johnson (NYSE:JNJ) recently announced positive results from a phase 2 study of its RSV vaccine candidate. In this Motley Fool Live video recorded on Oct. 6, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J set a high bar for Pfizer (NYSE:PFE) and GlaxoSmithKline (NYSE:GSK) to top.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Johnson & Johnson announced on Sunday positive results from a fairly large-size phase 2 study of its experimental RSV vaccine. Do you think these results set a tough bar for Pfizer and GlaxoSmithKline, both of which are also developing RSV vaccines?\n\nBrian Orelli: This is a phase 2 study that had 5,800 adults over the age of 65.",
"sentiment": 0.4767,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Example response
marketaux is Incredibly Powerful and Easy-to-Use
Get the latest financial and stock market news from top news sources. Use our API to access clean and relevant financial news and analysis.
Over 200,000 entities tracked every minute
We track over 80 global markets with news from more than 5,000 quality sources in 30+ languages.
Concise analysis of only relevant text allows us to generate superior analytics for stocks and other entities.
VIEW SUPPORTED ENTITIESAdvanced language processing technology
Our NLP technology allows us to identify critical details within news articles.
Our tracked entities include stocks, indices, ETFs, commodities, mutual funds, futures, currencies and crypto, complete with relevant analysis.
GET FREE API KEY
Frequent Asked Questions
Our service is 100% free to use on our free plan - no payment details are required.
Each time the API is used to access financial news or analysis data, 1 API request is added to your daily usage. The number of requests allowed for your account depends on which subscription plan you are on.
Yes, paying annually will provide you 2 months free per year (20% discount). To register for a yearly plan, simply go to our pricing page while logged in and select a plan and you will be prompted to pay monthly or annually.